Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early anifrolumab introduction in first remission induction therapy for systemic lupus erythematosus
jRCTs031230358Recruiting
- Sponsor
- University of Tsukuba Hospital
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of anifrolumab and prednisolone in systemic lupus erythematosus (SLE), sponsored by University of Tsukuba Hospital. Primary endpoint: Percentage of patients achieving LLDAS at 12 weeks. Started Dec 2023; status: recruiting.
02
Drugs
anifrolumabprednisolone
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCTs031230358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230358.